Tags

Type your tag names separated by a space and hit enter

Once daily intranasal fluticasone propionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis.

Abstract

BACKGROUND

Fluticasone propionate aqueous nasal spray, a new topical corticosteroid, has been proved to be an effective treatment for seasonal allergic rhinitis.

OBJECTIVES

We studied the effect of fluticasone propionate on nasal symptoms, circulating eosinophils, and nasal inflammation in patients with seasonal allergic rhinitis after high-load pollen exposure. Moreover, we examined its efficacy in preventing the increase in bronchial responsiveness to methacholine (PD20) during the pollen season.

METHODS

We conducted a double-blind, placebo-controlled, parallel-group study in patients who had a history of allergic rhinitis in response to pollens of grass and Parietaria species and were living in northern Italy. After a run-in period of 2 weeks, 24 patients were treated with fluticasone propionate (200 micrograms, once daily), and 26 patients received matched placebo for 6 weeks, starting from the beginning of the pollen season. Assessment of efficacy was based on scores of daily nasal symptoms. Nasal lavage was performed at the end of the season, and differential cell count was expressed as percent of total cells. PD20 methacholine was measured at the beginning and end of the season and after the season had ended.

RESULTS

Fluticasone propionate significantly reduced nasal obstruction, itching, and rhinorrhea. Eosinophils in blood (p < 0.01) and nasal lavage (p < 0.001) were also reduced. Moreover, fluticasone significantly attenuated the decrease in mean PD20 methacholine (from 1.95 to 0.89 mg) compared with placebo (from 1.38 to 0.37 mg: p < 0.01). After the season, no difference in PD20 methacholine was found between treatment groups.

CONCLUSIONS

The results of this study indicate that fluticasone propionate is effective in decreasing nasal symptoms and eosinophil inflammation in patients with seasonal allergic rhinitis after high-load pollen exposure. Our results also demonstrate that treatment with fluticasone propionate partially prevents the increase in bronchial responsiveness provoked by the inhalation of seasonal pollens in allergic rhinitis.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Servizio di Fisiopatologia Respiratoria G. Campari, Sesto San Giovanni, Italy.

    , , , ,

    Source

    MeSH

    Administration, Intranasal
    Adolescent
    Adult
    Androstadienes
    Anti-Inflammatory Agents
    Blood Proteins
    Bronchial Hyperreactivity
    Bronchial Provocation Tests
    Double-Blind Method
    Drug Administration Schedule
    Eosinophil Granule Proteins
    Eosinophilia
    Female
    Fluticasone
    Humans
    Hydrocortisone
    Male
    Methacholine Chloride
    Middle Aged
    Nasal Lavage Fluid
    Pollen
    Rhinitis, Allergic, Seasonal
    Ribonucleases
    Seasons

    Pub Type(s)

    Clinical Trial
    Journal Article
    Randomized Controlled Trial

    Language

    eng

    PubMed ID

    8757203

    Citation

    Foresi, A, et al. "Once Daily Intranasal Fluticasone Propionate (200 Micrograms) Reduces Nasal Symptoms and Inflammation but Also Attenuates the Increase in Bronchial Responsiveness During the Pollen Season in Allergic Rhinitis." The Journal of Allergy and Clinical Immunology, vol. 98, no. 2, 1996, pp. 274-82.
    Foresi A, Pelucchi A, Gherson G, et al. Once daily intranasal fluticasone propionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol. 1996;98(2):274-82.
    Foresi, A., Pelucchi, A., Gherson, G., Mastropasqua, B., Chiapparino, A., & Testi, R. (1996). Once daily intranasal fluticasone propionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. The Journal of Allergy and Clinical Immunology, 98(2), pp. 274-82.
    Foresi A, et al. Once Daily Intranasal Fluticasone Propionate (200 Micrograms) Reduces Nasal Symptoms and Inflammation but Also Attenuates the Increase in Bronchial Responsiveness During the Pollen Season in Allergic Rhinitis. J Allergy Clin Immunol. 1996;98(2):274-82. PubMed PMID: 8757203.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Once daily intranasal fluticasone propionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. AU - Foresi,A, AU - Pelucchi,A, AU - Gherson,G, AU - Mastropasqua,B, AU - Chiapparino,A, AU - Testi,R, PY - 1996/8/1/pubmed PY - 1996/8/1/medline PY - 1996/8/1/entrez SP - 274 EP - 82 JF - The Journal of allergy and clinical immunology JO - J. Allergy Clin. Immunol. VL - 98 IS - 2 N2 - BACKGROUND: Fluticasone propionate aqueous nasal spray, a new topical corticosteroid, has been proved to be an effective treatment for seasonal allergic rhinitis. OBJECTIVES: We studied the effect of fluticasone propionate on nasal symptoms, circulating eosinophils, and nasal inflammation in patients with seasonal allergic rhinitis after high-load pollen exposure. Moreover, we examined its efficacy in preventing the increase in bronchial responsiveness to methacholine (PD20) during the pollen season. METHODS: We conducted a double-blind, placebo-controlled, parallel-group study in patients who had a history of allergic rhinitis in response to pollens of grass and Parietaria species and were living in northern Italy. After a run-in period of 2 weeks, 24 patients were treated with fluticasone propionate (200 micrograms, once daily), and 26 patients received matched placebo for 6 weeks, starting from the beginning of the pollen season. Assessment of efficacy was based on scores of daily nasal symptoms. Nasal lavage was performed at the end of the season, and differential cell count was expressed as percent of total cells. PD20 methacholine was measured at the beginning and end of the season and after the season had ended. RESULTS: Fluticasone propionate significantly reduced nasal obstruction, itching, and rhinorrhea. Eosinophils in blood (p < 0.01) and nasal lavage (p < 0.001) were also reduced. Moreover, fluticasone significantly attenuated the decrease in mean PD20 methacholine (from 1.95 to 0.89 mg) compared with placebo (from 1.38 to 0.37 mg: p < 0.01). After the season, no difference in PD20 methacholine was found between treatment groups. CONCLUSIONS: The results of this study indicate that fluticasone propionate is effective in decreasing nasal symptoms and eosinophil inflammation in patients with seasonal allergic rhinitis after high-load pollen exposure. Our results also demonstrate that treatment with fluticasone propionate partially prevents the increase in bronchial responsiveness provoked by the inhalation of seasonal pollens in allergic rhinitis. SN - 0091-6749 UR - https://www.unboundmedicine.com/medline/citation/8757203/Once_daily_intranasal_fluticasone_propionate__200_micrograms__reduces_nasal_symptoms_and_inflammation_but_also_attenuates_the_increase_in_bronchial_responsiveness_during_the_pollen_season_in_allergic_rhinitis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0091674996002114 DB - PRIME DP - Unbound Medicine ER -